The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Patients Have No More Skin to Give: Dr. William Harvey Testifies on Rheumatology Issues before Senate Committee

Patients Have No More Skin to Give: Dr. William Harvey Testifies on Rheumatology Issues before Senate Committee

February 16, 2018 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Prior authorization treatment delays, the preferred status conferred on some drugs by pharmacy benefit managers and exorbitant co-payments were among the issues brought before the U.S. Senate Special Committee on Aging on Wednesday, Feb. 7. William F. Harvey, MD, MSc, FACR, a practicing rheumatologist at Tufts Medical Center in Boston and volunteer on the ACR Board of Directors, testified before the committee, highlighting issues of import to rheumatologists and their patients.

You Might Also Like
  • The ACR Testifies before Congress on Patient Access
  • Give Rheumatology Patients a Helping Hand
  • U.S. Senate Finance Committee Invites Pharma Execs to Testify
Explore This Issue
April 2018
Also By This Author
  • ACR Insurance Subcommittee Responds to Payer Policies

“Choosing the right therapy for a patient is a complex medical decision that considers other conditions and medications the patient may have, balancing the risk of side effects and many patient-specific factors,” said Dr. Harvey. “… Factors to consider when choosing the right biologic therapy include medications already tried, history of infections and malignancy, and the ability to administer the medication to themselves. But overwhelmingly, the primary factor in the decision is which one is covered best by insurance. …

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Each of these medications require a prior authorization. Each insurance company has a different set of forms requiring somewhat different types of information. Most require that the patient have their medication provided by a specific pharmacy. This is because the insurance companies negotiate, often through pharmacy benefit managers, price discounts in exchange for preferred status on the insurance formulary. If a provider wishes to prescribe a medication that is not preferred, the prior authorization will be denied, and the provider must go through an escalating appeals process that may involve talking to a clerk, a pharmacist, a nurse, a “peer review” (another MD but typically not a rheumatologist), a same specialty review and, in the case of Medicare, an Administrative Law Judge.”

Dr. Harvey asked the committee for regulations requiring that insurance companies follow a standard, transparent process for documenting, evaluating and approving prior authorization requests.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Harvey also endorsed the Patient Access to Treatment Act (H.R. 2999) or other efforts that limit or cap out-of-pocket expenses for patients, saying that co-pays “were originally conceived to require consumers, patients, to have some skin in the game.” But out-of-pocket expenses for rheumatology patients are substantial, said Dr. Harvey. “Patients did not choose their disease, nor do they control the high cost of developing and marketing the only therapies left to treat their condition. Asking them to pay their ‘fair share’ is immoral and indefensible when it leads to medical bankruptcy. Further, these patients are more likely to leave the workforce, ending up on government subsidized disability, which further burdens the federal government. I can say unequivocally that many patients with rheumatoid arthritis or its close cousin arthritis associated with psoriasis, that many patients have no skin left to give.”

Pages: 1 2 | Single Page

Filed Under: From the College, Legislation & Advocacy, Professional Topics Tagged With: Dr. William Harvey, pharmacy benefit managers, prior authorization, U.S. Senate Special Committee on Aging, William Harvey testimonyIssue: April 2018

You Might Also Like:
  • The ACR Testifies before Congress on Patient Access
  • Give Rheumatology Patients a Helping Hand
  • U.S. Senate Finance Committee Invites Pharma Execs to Testify
  • ACR Issues Position Statements on Key Rheumatology Issues

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)